Minerva Neurosciences | NERV - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Adma Biologics USD 76.41M 6.8M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cipla INR 59.27B 1.71B 2026-03
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Takeda JPY 1.11T 85.29B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12